AtomVie Global Radiopharma Strengthens Leadership with New Chief Business Officer Appointment

Strengthening Leadership at AtomVie Global Radiopharma

On December 5, 2024, AtomVie Global Radiopharma, a prominent player in the radiopharmaceutical contract development and manufacturing organization (CDMO) sector, made a significant announcement regarding its leadership. The company revealed the appointment of Dr. Pratibhash (Bosh) Chattopadhyay as its new Chief Business Officer. This strategic move comes at a crucial moment as AtomVie gears up for substantial growth and prepares to enhance its manufacturing capabilities.

Dr. Chattopadhyay brings over 25 years of in-depth experience in the life sciences field. Having an extensive background in spearheading commercialization initiatives, he has established a remarkable reputation for his work in oncology technologies. His career has spanned multiple sectors within the pharmaceutical industry, including contract development and manufacturing, formulation development, and advanced drug delivery systems. His previous positions at leading companies such as BASF, Catalent, and Matica Biotechnology have equipped him with the necessary technical and commercial expertise required to lead AtomVie towards its ambitious goals.

Holding a Doctorate in Chemical Engineering from Auburn University and an MBA from Duke University’s Fuqua School of Business, Dr. Chattopadhyay is not only academically accomplished but also highly regarded for his strategic contributions to pharmaceutical product development and commercialization efforts.

A Critical Expansion Phase

Dr. Chattopadhyay's appointment is particularly timely, aligning with AtomVie’s strategic expansion phase. The company is in the process of launching a state-of-the-art facility, expected to be operational in 2025. This facility is set to dramatically increase AtomVie’s production capacity—more than tenfold—reflecting the rising global demand for high-quality radiopharmaceuticals.

With this new capacity, AtomVie aims to solidify its position in the market by providing comprehensive clinical and commercial manufacturing support. As Dr. Chattopadhyay joins the firm, he is poised to leverage his experience to foster collaborations with partners, essentially revolutionizing patient care through improved access to innovative treatments.

In a statement following his appointment, Dr. Chattopadhyay expressed his enthusiasm, stating, "I am thrilled to join AtomVie at such an exciting time in its growth. The commitment to enhancing radiopharmaceutical manufacturing capacity and pioneering advanced therapeutic solutions reflects the company's deep dedication to transforming patient care. I look forward to contributing to AtomVie's mission and working alongside a talented team and global partners to deliver impactful treatments that address unmet needs and improve quality of life for patients globally."

Support from Leadership

Bruno Paquin, the CEO of AtomVie, also shared his excitement regarding Dr. Chattopadhyay's arrival. He noted, "Dr. Chattopadhyay's deep pharmaceutical industry knowledge and proven ability to lead commercial strategy and innovation make him a valuable addition to our leadership team. His expertise will be instrumental in broadening our partnerships to fulfill the growing global need for radiopharmaceuticals. We are excited to welcome Dr. Chattopadhyay onboard and look forward to his contributions towards AtomVie's success and leadership in the radiopharmaceutical CDMO industry."

About AtomVie Global Radiopharma

AtomVie is recognized as a leading CDMO for GMP manufacturing and global distribution of clinical and commercial radiopharmaceuticals. The company provides a comprehensive range of scientific, technical, regulatory, quality, logistics, and business support, tailored to develop radiopharmaceuticals all the way from clinical trials to commercial success. Currently, AtomVie caters to clients conducting studies in over 25 countries worldwide. With the new advanced 72,300 sq ft facility in Hamilton, ON, set to launch in 2025, AtomVie is well-positioned for robust growth and enhanced service delivery in the evolving radiopharmaceutical landscape.

For additional information, visit AtomVie Global Radiopharma.